COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease (LINC-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02697734
Recruitment Status : Active, not recruiting
First Posted : March 3, 2016
Last Update Posted : April 21, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 19, 2019
Estimated Study Completion Date : January 25, 2021
Certification/Extension First Submitted : August 28, 2019